Company Overview of Fumapharm AG
As of May 31, 2006, Fumapharm AG was acquired by Biogen Idec, Inc. Fumapharm AG, a pharmaceutical company, develops therapeutics. Its products include FUMADERM for the treatment of psoriasis; and BG-12 for the treatment of multiple sclerosis and psoriasis. The company was founded in 1983 and is headquartered in Luzern, Switzerland.
Founded in 1983
41 41 371 20 46
41 41 371 20 48
Key Executives for Fumapharm AG
Fumapharm AG does not have any Key Executives recorded.
Similar Private Companies By Industry
|Acino International AG||Europe|
|Albea Pharmaceuticals AG||Europe|
|Alpen Pharma AG||Europe|
|Alpex Pharma SA||Europe|
|Amring Pharmaceuticals SA||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
To contact Fumapharm AG, please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.